Late last year, French legislators quietly slipped a measure into the country's 2014 budget legislation that would allow pharmacists to substitute inexpensive biosimilar drugs for pricier biotech brands. While not a full-out assault on branded biologics, it would make France the first European country to substitute the cheaper drugs, and the pharma industry is doing everything it can to derail that move before France's Administrative Supreme Court decrees it into effect.
The Persian Gulf is the newest emerging market for Big Pharma, the Wall Street Journal reports. Drugmakers have jumped on that opportunity, as evidenced by the number of new plants and distribution facilities they are putting there.
Are the BRIC countries passé in Big Pharma? Not exactly. But multinational pharma's newest trend lies in the Persian Gulf, the Wall Street Journal reports.
If Big Pharma should consider hiving off extraneous business units, then why not Big Generics? Goldman Sachs analyst Jami Rubin, an early champion of the pharma breakup, figures Teva Pharmaceutical Industries could try it.
Big Pharma wants the U.S. to pull a big-gorilla act in India. With patents revoked and cheap generics foisted on them ahead of schedule--and more early copycats possibly on their way--multinational drugmakers are lobbying for an intervention.
First, South Africa proposed patent-law changes that would help foster generic drugs. Then, Big Pharma and its smaller colleagues in the country's pharma association hatched a counter-offensive: a $600,000 lobbying campaign against the measure. Now, Novo Nordisk has quit that group, the Innovative Pharmaceutical Association of South Africa (Ipasa), in protest.
South Africa's Minister of Health, Aaron Motsoaledi, lashed out on Friday at a report that Big Pharma is funding a PR campaign aimed at opposing new patent provisions favoring generic drugs, calling it "a conspiracy of satanic magnitude" that would lead to "genocide."
Big Pharma has more money in its pocket for deals. And Big Pharma still needs more M&A for post-patent-cliff rebuilding. But Big Pharma's buyout targets want more money.
Poor returns led drug developers to exit the antibiotics sector years ago, only for hospital-acquired infections to become a big, deadly and potentially lucrative problem. Big Pharma is returning to the sector, but two academics have a different idea: crowdsource discovery.
Who would argue that Big Pharma marketing isn't changing? Anyone? Well, get ready for even more, Adweek says. Combine Obamacare with technology, social media, Big Data and payer demands, and you have a prescription for pharma sales that's as different from the old days of DTC advertising on network TV as "Father Knows Best" is from "Breaking Bad."